|Bid||138.10 x 500|
|Ask||138.75 x 100|
|Day's Range||137.10 - 138.93|
|52 Week Range||96.93 - 138.93|
|PE Ratio (TTM)||51.76|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors have had an appetite for risk recently, sending certain market sectors soaring.
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
View more earnings on CURE See more from Benzinga Focusing On An Alternative To S&P 500 ETFs A New ETF For Low Vol ETFs © 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved....